Blockchain specialists raise $200M in Series C funding

Ripple, a San Francisco-based technology company focused on blockchain, has raised $200 million in Series C funding. Tetragon led the funding round, with SBI Holdings and Route 66 Ventures also investing.  

“We are in a strong financial position to execute against our vision,” Ripple CEO Brad Garlinghouse said in a prepared statement. “As others in the blockchain space have slowed their growth or even shut down, we have accelerated our momentum and industry leadership throughout 2019.”

The funding round caps off a massively successful year for Ripple. RippleNet, the company’s global payments network, now has more than 300 customers from more than 45 countries throughout the world. XRP, the cryptocurrency used by RippleNet, is currently priced at $0.19.

The funds are expected to go toward increasing the worldwide adoption of RippleNet and hiring new employees as the company works to “better serve its growing community of customers and partners.”

The market for blockchain technology in healthcare could exceed $500 million by 2022, according to a recent report from Frost & Sullivan.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.